The triplet regimen of berdomide, daratumumab (Darzalex), and dexamethasone has led to deepening responses in newly diagnosed, transplant-ineligible patients with multiple myeloma.

Progress has been made in identifying and treating the disease, but the impact of federal cuts is yet to be borne out.

News involving the treatment of multiple myeloma this year was highlighted by talk of a potential cure with a single infusion ...

The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and ...

The coming of age of chimeric antigen receptor (CAR) T-cell therapy, the selection of postinduction therapy on the basis of residual disease activity, and a novel drug delivery system are among the ...

Multiple myeloma is preceded by an asymptomatic expansion of clonal plasma cells that is detected clinically and described as smoldering multiple myeloma. Studies have identified a fraction of cases ...

Not a day goes by in clinic without a patient asking about the recent New York Times article on multiple myeloma: "Doc, is there really a cure now? I want this treatment." The article was boldly ...

Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps ...

Sundar Jagannath, MBBS, highlights long-term follow-up data from the phase 1b/2 CARTITUDE-1 trial, showing durable responses and potential cures with ciltacabtagene autoleucel in patients with ...

At the recent American Society of Clinical Oncology (ASCO) meeting, early data from the DREAMM-20 trial showed that the naked B-cell maturation antigen (BCMA)-targeted monoclonal antibody belantamab - ...

TORONTO -- Linvoseltamab (Lynozyfic) appeared effective in patients with high-risk smoldering multiple myeloma (HR-SMM), according to preliminary phase II trial data. With a median follow-up of 3.9 ...